A pluripotent road to immunoengineering

Adoptive immunotherapy, particularly chimeric antigen receptor (CAR)-T cells, has had considerable success in treating haematological malignancies. However, the variability, time commitment and cost of engineering cells limit their application. Human pluripotent stem (hPS) cells could provide an off-the-shelf, cheaper and scalable solution.